RT Journal Article
SR Electronic
T1 The INCH Trial – Induction Chemotherapy in Patients With Bulky Anal Canal Cancer: Evaluation of the Pilot Phase
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3187
OP 3191
DO 10.21873/anticanres.15105
VO 41
IS 6
A1 DE FELICE, FRANCESCA
A1 FALLARINO, ALESSIA
A1 IAFRATE, FRANCO
A1 MAIURI, VERONICA
A1 GALLONI, GIOVANNI
A1 COLONNA, GIOVANNI TURRIZIANI
A1 DE PIETRO, RAFFAELLA
A1 CHIARELLO, GIUSEPPINA
A1 MARCHETTI, CLAUDIA
A1 BULZONETTI, NADIA
A1 MUSIO, DANIELA
A1 TOMBOLINI, VINCENZO
YR 2021
UL http://ar.iiarjournals.org/content/41/6/3187.abstract
AB Aim: To assess feasibility, complications and efficacy of induction chemotherapy followed by standard chemoradiotherapy in patients with bulky anal canal cancer. Patients and Methods: Patients with squamous cell carcinoma of the anal canal, staged bulky tumor with or without nodal involvement were prospectively enrolled. Before standard chemoradiotherapy, patients received induction chemotherapy with 3 cycles of 75 mg/m2 cisplatin and 750 mg/m2 5-fluorouracil. Patients were followed-up routinely until recurrence or death. Results: Seven patients with bulky anal canal cancer were evaluable for this pilot phase of the study. All patients had human papillomavirus-negative disease. Five completed the scheduled induction chemotherapy and all patients completed the programmed concomitant chemoradiotherapy. None had severe hematological toxicity. The majority of patients (6/7) had tumor downsizing after induction treatment. Six months after chemoradiotherapy, complete response was documented in three patients and salvage surgery was performed in two cases. With a median follow-up of 38 months (range=28-48 months), two patients are disease-free survivors. Conclusion: Induction chemotherapy has the potential to become a standard approach in patients with bulky human papillomavirus-negative anal canal cancer.